8-K current report · filed Aug 11, 2026

Immunome Inc. (IMNM) 8-K Current Report: August 11, 2026

Item EX-99.1Item 2.02IMNM overview

Short answer

Immunome Inc. (IMNM) filed an 8-K current report with the SEC on August 11, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results for quarter ended June 30, 2026 announced.

Immunome Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial results for quarter ended June 30, 2026 announced
  • Business update included in Exhibit 99.1 press release
  • Investor focus: financial performance and development-program updates in the attached release

Item EX-99.1 · Exhibit EX-99.1

  • FDA accepted varegacestat NDA; PDUFA decision target April 28, 2027, creating a defined regulatory catalyst
  • Phase 3 RINGSIDE showed 84% lower progression-or-death risk and 56% objective response rate versus 9% placebo
  • Cash, equivalents and marketable securities totaled $520.0M, with management projecting operational funding into 2028
  • Quarterly net loss reached $73.1M as R&D increased to $59.9M and G&A to $18.3M
  • IM-1617 and IM-3050 entered Phase 1, expanding clinical-stage ADC and radioligand opportunities beyond varegacestat

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Immunome Inc. 8-K filings

Get the next IMNM 8-K as it lands

Follow IMNM for push alerts, or ask the research agent what this filing means.